From Nasdaq: 2025-06-11 23:20:00

Insmed Inc. (INSM) priced a public offering of 7.81 million shares of common stock at $96.00 per share, expecting gross proceeds of $750 million. The company granted underwriters a 30-day option to purchase an additional 1.17 million shares. Proceeds will fund research and development of brensocatib, pre-commercial and commercialization activities, and other corporate purposes. Goldman Sachs & Co. LLC, Leerink Partners, BofA Securities, Jefferies, and J.P. Morgan are joint book-running managers, with Stifel as co-lead manager. The offering is set to close on June 13, 2025.



Read more at Nasdaq: Insmed Prices Public Offering Of About 7.81 Mln Shares At $96.00/shr